Sensory neuronopathy is described in association with the Sj？gren's syndrome (SS). We studied a 55-year-old woman with a 4-year history of progressive asymmetric numbness, distal tingling, and burning sensation in upper and lower limbs. In a few months, she developed ataxia with increased hypoanaesthesia. Electrodiagnostic tests revealed undetectable distal and proximal sensory nerve action potential in upper and lower limbs. Cervical spine magnetic resonance showed a signal hyperintensity of posterior columns. Previous treatment with high-dose glucocorticoids and azathioprine was ineffective. A combined treatment with intravenous immunoglobulin and mycophenolate mofetil was followed by a progressive and persistent improvement. This case documented the efficacy and the safety of the coadministration of intravenous immunoglobulin and mycophenolate mofetil in sensory neuronopathy associated with SS refractory to conventional immunosuppressive therapy. 1. Introduction Central nervous system involvement in Sj？gren’s syndrome (SS) is rarely reported and may be severe and varied [1]. Sensory neuronopathy (or sensory ganglionopathy, SN) is a distinctive neuropathy of SS, accounting for 15–20% of all neuropathies seen in this condition [2]. A sensory neuropathy is often the presenting feature of SS, and, therefore, a high index of suspicion is required, particularly in female patients with non-length-dependent, painful, or ataxic sensory neuropathy or those with trigeminal sensory and autonomic involvement [3]. At the onset of SN, numbness, tingling, burning, and pain sensations are reported in all limbs, usually with asymmetric distribution. With the disease progression, the sensory disturbances can involve the trunk, the face or they develop into a symmetric way. On examination, degeneration of large sensory neurons leads to gait ataxia, proprioceptive sensory loss, and widespread deep tendon areflexia [3]. When smaller sensory neurons are affected, deficits are those of hypoesthesia to pain and thermal stimuli with hyperacute pain. Autonomic nervous system involvement may cause fixed tachycardia, orthostatic hypotension, and gastrointestinal pseudo-obstruction. The response to treatment is usually poor, even with glucocorticoids, immunosuppressants, and plasmapheresis [3]. Here we report the case of a woman with primary SS who presented with SN that was successfully managed with intravenous immunoglobulin and mycophenolate mofetil coadministration. 2. Case Report In 2001, a 55-year-old woman presented with progressive asymmetric numbness distal tingling and
References
[1]
G. J. Tobón, J. O. Pers, V. Devauchelle-Pensec, et al., “Neurological disorders in primary Sj？gren's syndrome,” Autoimmune Diseases, vol. 2012, Article ID 645967, 11 pages, 2012.
[2]
S. I. Mellgren, L. G. G？ransson, and R. Omdal, “Primary Sj？gren's syndrome associated neuropathy,” Canadian Journal of Neurological Sciences, vol. 34, no. 3, pp. 280–287, 2007.
[3]
A. Sghirlanzoni, D. Pareyson, and G. Lauria, “Sensory neuron diseases,” Lancet Neurology, vol. 4, no. 6, pp. 349–361, 2005.
[4]
C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sj？gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002.
[5]
J. W. Griffin, D. R. Cornblath, E. Alexander et al., “Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sj？gren's syndrome,” Annals of Neurology, vol. 27, no. 3, pp. 304–315, 1990.
[6]
J. A. Molina, J. Benito-Leon, F. Bermejo, F. J. Jimenez-Jimenez, and J. Olivan, “Intravenous immunoglobulin therapy in sensory neuropathy associated with Sj？gren's syndrome,” Journal of Neurology Neurosurgery and Psychiatry, vol. 60, no. 6, p. 699, 1996.
[7]
Y. Takahashi, T. Takata, M. Hoshino, M. Sakurai, and I. Kanazawa, “Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sj？gren's syndrome,” Neurology, vol. 60, no. 3, pp. 503–505, 2003.
[8]
S. Rist, J. Sellam, E. Hachulla, et al., “Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sj？gren's syndrome: a national multicentric retrospective study,” Arthritis Care & Research, vol. 63, pp. 1339–1344, 2011.
[9]
P. Willeke, B. Schlüter, H. Becker, H. Schotte, W. Domschke, and M. Gaubitz, “Mycophenolate sodium treatment in patients with primary Sj？gren's syndrome: a pilot trial,” Arthritis Research and Therapy, vol. 9, no. 6, pp. 115–121, 2007.
[10]
Y. Murata, K. Maeda, H. Kawai et al., “Antiganglion neuron antibodies correlate with neuropathy in Sj？gren's syndrome,” NeuroReport, vol. 16, no. 7, pp. 677–681, 2005.
[11]
J. F. Seite, Y. Shoenfeld, P. Youinou, and S. Hillion, “What is the contents of the magic draft IVIg?” Autoimmunity Reviews, vol. 7, no. 6, pp. 435–439, 2008.
[12]
M. G. Danieli, L. Pettinari, R. Moretti, F. Logullo, and A. Gabrielli, “Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application,” Autoimmunity Reviews, vol. 10, no. 3, pp. 144–149, 2011.
[13]
A. Kessel, H. Ammuri, R. Peri et al., “Intravenous immunoglobulin therapy affects t regulatory cells by increasing their suppressive function,” Journal of Immunology, vol. 179, no. 8, pp. 5571–5575, 2007.
[14]
J. Vani, S. Elluru, V. S. Negi et al., “Role of natural antibodies in immune homeostasis: IVIg perspective,” Autoimmunity Reviews, vol. 7, no. 6, pp. 440–444, 2008.
